Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilvegostomig + S-1
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
rilvegostomig + S-1 is a combination therapy being developed by AstraZeneca for the treatment of biliary tract cancer. It consists of rilvegostomig (AZD2936), a bispecific monoclonal antibody that simultaneously targets the PD-1 and TIGIT immune checkpoints, and S-1, an oral fluoropyrimidine chemotherapy agent. S-1 itself is a multi-component drug containing tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor). The regimen is currently being evaluated in the Phase III ARTEMIDE-Biliary01 trial as an adjuvant treatment for patients with resected biliary tract cancer who are at high risk of recurrence. By combining immune checkpoint blockade with cytotoxic chemotherapy, the treatment aims to enhance the immune system's ability to target cancer cells and eliminate residual disease following surgical resection.
- Brand names
- TS-1TS1TS 1Teysuno
- Other names
- rilvegostomig + tegafur + gimeracil + oteracilAZD2936 + S-1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)TIGIT (T cell immunoreceptor with Ig and ITIM domains)OPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on rilvegostomig + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilvegostomig + S-1.